DK2350266T3 - Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion - Google Patents
Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion Download PDFInfo
- Publication number
- DK2350266T3 DK2350266T3 DK09827049.9T DK09827049T DK2350266T3 DK 2350266 T3 DK2350266 T3 DK 2350266T3 DK 09827049 T DK09827049 T DK 09827049T DK 2350266 T3 DK2350266 T3 DK 2350266T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- pancreatic
- stro
- cell
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
Claims (15)
1. STR0-1 + -ce I le r til anvendelse i en fremgangsmåde til forbedring af pankreatisk funktion hos et individ med behov derfor.
2. Celler til anvendelse ifølge krav 1, hvor anvendelse af cel lerne: (i) inducerer eller fremmer regeneration af pankreatiske beta-celler og/eIler Langerhansske øer; og/el ler (i i) reducerer blodsukkerniveauer og/el ler øger insulinniveauer i blod/serum; og/el I er (i i i) øger antallet af pankreatiske beta-celler og/el ler øger antallet af pankreatiske beta-celler i forhold til pankreatiske alfa-celler og/el ler reducerer antallet af pankreatiske alfa-celler og/el ler øger antallet af Langerhansske øer; og/eller (iv) øger pankreatisk og duodenal homeobox-faktor-1-(PDX-1) ekspression og/eller øger antallet af PDX-1 udtrykkende celler i en pankreas; og/eller (v) inducerer eller fremmer arte r iogenese eller angiogenese i pankreas.
3. Celler til anvendelse ifølge krav 1 eller krav 2, hvor individet lider af en pankreatisk dysfunktion forbundet med pankreas’ endokrine og/eller exokrine funktion.
4. Celler til anvendelse ifølge krav 3, hvor pankreatisk dysfunkt ionen: (a) er forbundet med eller forårsager afvigende niveauer af insulin, glucagon, somatostatin, pankreatisk polypeptid, trypsinogen, chymotrypsinogen, elastase, carboxypeptidase, pankreatisk lipase eller amylase; (b) er forbundet med eller forårsager malabsorption af nær ingsstof fer; (c) er forbundet med pancreatitis, pankreatisk insufficiens, erhvervet autoimmun deficienssyndrom, cancer, cystisk fibrose eller Zol I inger-EI I ison-syndrom; (d) resulterer i hypoglykæmi eller hyperg lykæmi, reducerede aminosyren iveauer i serum, proteinuri eller nekrolytisk migrerende erytem; eller (e) er forbundet med eller forårsager en forstyrrelse i carbohydratstofskifte.
5. Celler til anvendelse ifølge krav 4, hvor det afvigende niveau af glucagon er forårsaget af en glucagonsekreterende tumor.
6. Celler til anvendelse ifølge krav 4, hvor forstyrrelsen i carbohydratstofskifte er forårsaget af pankreas’ reducerede insulinproduktion eller af pankreas’ reducerede amylaseproduktion.
7. Celler til anvendelse ifølge krav 4 eller krav 6, hvor forstyrrelsen i carbohydratstofskifte er diabetes me 11 i t u s .
8. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -ceI lerne deraf er beregnet til administration direkte ind i et individs blodbane.
9. Celler til anvendelse ifølge krav 10, hvor STRO-Γ- cellerne er beregnet til administration i n t raarter ie11.
10. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -ce 11 e rne administreret til individet er STRO-1bn og/el ler udtrykker ikke-vævsspecifik alkalisk phosphatase (TNAP).
11. Celler til anvendelse ifølge et hvilket som helst af de foregående krav til behandling eller forsinkelse af progression af pankreatisk dysfunktion, hvor STRO-Γ- cellerne er beregnet til administration efter diagnosticering af lidelsen.
12. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -cel Ierne er beregnet til administration i form af en sammensætning omfattende STRO-1+-ce I le rne og et bærestof og/el ler hjælpestof og eventuelt en faktor, der inducerer eller øger differentiering af progen i to reel I e r til vaskulære celler eller sammensætningen omfatter en vævsspecifik engageret celle.
13. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -ce 11 e rne tidligere har væ re t dyrket in vitro.
14. Anvendelse af STRO-1 + -ce I le r i fremstillingen af et medikament til forbedring af pankreatisk funktion hos et individ med behov derfor.
15. Anvendelse ifølge krav 14, hvor medikamentet er beregnet til: (i) induktion eller fremme af regeneration af pankreatiske beta-celler og/eIler Langerhansske øer; og/eI ler (ii) reduktion af blodsukkerniveauer og/eller forøgelse af insulinniveauer i blod/serum; og/el ler (i i i) forøgelse af antallet af pankreatiske betaceller og/el ler forøgelse af antallet af pankreatiske beta-celler i forhold til pankreatiske alfa-celler og/el ler reduktion af antallet af pankreatiske alfaceller og/el ler forøgelse af antallet af Langerhansske øer; og/e 11e r (iv) forøgelse af pankreatisk og duodenal homeobox-faktor-1- (PDX-1) ekspression og/el ler forøgelse af antallet af PDX-1-udtrykkende celler i en pankreas; og/eI ler (v) induktion eller fremme af ar te r i ogenese eller angiogenese i pankreas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19979608P | 2008-11-20 | 2008-11-20 | |
PCT/AU2009/001511 WO2010057260A1 (en) | 2008-11-20 | 2009-11-19 | Method for treating or preventing a pancreatic dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2350266T3 true DK2350266T3 (da) | 2015-11-02 |
Family
ID=42197754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09827049.9T DK2350266T3 (da) | 2008-11-20 | 2009-11-19 | Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion |
Country Status (11)
Country | Link |
---|---|
US (3) | US8894972B2 (da) |
EP (2) | EP2350266B1 (da) |
JP (6) | JP5891034B2 (da) |
KR (2) | KR101832497B1 (da) |
CN (3) | CN104546912B (da) |
AU (1) | AU2009317874B2 (da) |
CA (1) | CA2744228C (da) |
DK (1) | DK2350266T3 (da) |
ES (2) | ES2550795T3 (da) |
HK (2) | HK1197186A1 (da) |
WO (1) | WO2010057260A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546912B (zh) | 2008-11-20 | 2019-11-08 | 中胚有限公司 | 用于治疗胰功能异常的方法 |
SI2403605T1 (sl) | 2009-03-05 | 2015-11-30 | President And Fellows Of Harvard College | Sestavki, ki obsegajo aP2-specifično protitelo ali njegov fragment, za uporabo pri zdravljenju diabetesa, intolerance za glukozo ali z debelostjo povzročene inzulinske rezistence |
EP3366298B1 (en) * | 2010-07-02 | 2020-08-19 | Mesoblast, Inc. | Treatment of graft versus host disease |
AU2012255621A1 (en) | 2011-05-19 | 2013-05-02 | Mesoblast, Inc. | Methods for treating obesity and/or metabolic syndrome |
CN103841983B (zh) | 2011-06-03 | 2018-11-02 | 麦瑟布莱斯特公司 | 治疗或预防神经性疾病的方法 |
US9265796B2 (en) * | 2011-07-04 | 2016-02-23 | Mesoblast, Inc. | Methods of treating or preventing rheumatic disease |
AU2012279995C1 (en) | 2011-07-06 | 2019-10-24 | Cell Therapy Limited | Progenitor cells of mesodermal lineage |
CN104098682B (zh) * | 2013-04-03 | 2018-01-02 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
CN111840329B (zh) * | 2012-12-12 | 2024-10-15 | 麦瑟布莱斯特公司 | 内皮功能障碍和炎症的疾病的治疗 |
US20140314872A1 (en) * | 2013-04-22 | 2014-10-23 | Hans Klingemann | Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction |
CN104714021B (zh) * | 2013-12-12 | 2016-05-25 | 张曼 | 尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用 |
SG11201708323SA (en) | 2015-04-30 | 2017-11-29 | Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
EP3475299A4 (en) * | 2016-06-27 | 2020-03-18 | President and Fellows of Harvard College | COMPOUNDS USEFUL FOR TREATING METABOLIC DISORDERS |
EP3634479A4 (en) | 2017-06-09 | 2021-04-14 | President and Fellows of Harvard College | PROCESS FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING DEREGULATED LIPOGENESIS, DIABETES AND OTHER RELATED DISORDERS |
CN110959579A (zh) * | 2019-11-14 | 2020-04-07 | 顾隽 | 患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
DE19939781C2 (de) | 1999-08-21 | 2003-06-18 | Schott Glas | Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken |
US20040063204A1 (en) * | 2002-08-14 | 2004-04-01 | Lijun Yang | Bone marrow cell differentiation |
DE602004030823D1 (de) * | 2003-11-04 | 2011-02-10 | Biomaster Inc | Verfahren und system zur herstellung von stammzellen aus fettgewebe |
CN101506355B (zh) * | 2004-09-24 | 2012-06-27 | 成血管细胞系统公司 | 多能扩增间充质前体细胞子代(memp)及其应用 |
KR101682046B1 (ko) * | 2005-04-12 | 2016-12-02 | 메소블라스트, 아이엔씨. | 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리 |
GB0514785D0 (en) * | 2005-07-19 | 2005-08-24 | Innovia Films Ltd | Sealed ream wrap package and films suitable for forming such packages |
WO2007127408A2 (en) * | 2006-04-28 | 2007-11-08 | Tulane University Health Sciences Center | Methods for treating diabetes |
US20100247491A1 (en) * | 2007-02-01 | 2010-09-30 | Christof Westenfelder | Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure |
CN104546912B (zh) | 2008-11-20 | 2019-11-08 | 中胚有限公司 | 用于治疗胰功能异常的方法 |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
-
2009
- 2009-11-19 CN CN201410727242.0A patent/CN104546912B/zh active Active
- 2009-11-19 ES ES09827049.9T patent/ES2550795T3/es active Active
- 2009-11-19 JP JP2011536703A patent/JP5891034B2/ja active Active
- 2009-11-19 EP EP09827049.9A patent/EP2350266B1/en active Active
- 2009-11-19 CN CN201310652234.XA patent/CN103800370B/zh active Active
- 2009-11-19 ES ES15178550.8T patent/ES2651503T3/es active Active
- 2009-11-19 EP EP15178550.8A patent/EP3002329B1/en active Active
- 2009-11-19 US US13/129,180 patent/US8894972B2/en active Active
- 2009-11-19 CA CA2744228A patent/CA2744228C/en active Active
- 2009-11-19 DK DK09827049.9T patent/DK2350266T3/da active
- 2009-11-19 WO PCT/AU2009/001511 patent/WO2010057260A1/en active Application Filing
- 2009-11-19 KR KR1020117012519A patent/KR101832497B1/ko active IP Right Grant
- 2009-11-19 CN CN200980155054.2A patent/CN102307992B/zh active Active
- 2009-11-19 KR KR1020187004814A patent/KR102011609B1/ko active IP Right Grant
- 2009-11-19 AU AU2009317874A patent/AU2009317874B2/en active Active
-
2014
- 2014-10-27 HK HK14110752A patent/HK1197186A1/xx unknown
- 2014-11-07 US US14/535,827 patent/US9480713B2/en active Active
-
2015
- 2015-06-02 JP JP2015111995A patent/JP6499016B2/ja active Active
-
2016
- 2016-10-05 HK HK16111604.7A patent/HK1223396A1/zh unknown
- 2016-10-27 US US15/336,234 patent/US9968640B2/en active Active
-
2017
- 2017-06-07 JP JP2017112578A patent/JP2017214384A/ja not_active Withdrawn
-
2019
- 2019-09-06 JP JP2019162845A patent/JP7051770B2/ja active Active
-
2021
- 2021-10-29 JP JP2021177234A patent/JP2022031662A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023086994A patent/JP2023116536A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9968640B2 (en) | Method for treating or preventing a pancreatic dysfunction | |
AU2018247196A1 (en) | Methods for treating obesity and/or metabolic syndrome |